MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Net Income
-$7,020K
EPS
-$0.3
Unit: Thousand (K) dollars
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Research and development
4,684
4,106
7,715*
5,774
General and administrative
2,513
2,154
1,918*
2,020
Operating loss
-7,197
-6,260
-9,633*
-7,794
Finance income
177
210
243*
332
Net loss
-7,020
-6,050
-9,391*
-7,462
Effect of warrants modification, see note 6
-
-
-4,858*
2,429
Total net gain attributable to common shareholders
-7,020
-6,050
-4,533
-9,891
Basic EPS
-0.3
-0.26
-0.212
-0.44
Diluted EPS
-0.3
-0.26
-0.212
-0.44
Basic Average Shares
23,475,989
23,414,475
21,352,823
22,719,057
Diluted Average Shares
23,475,989
23,414,475
21,352,823
22,719,057
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Total net gain
attributable to common...
-$7,020K
Net loss
-$7,020K
(-10.83%↓ Y/Y)
Finance income
$177K
(-32.18%↓ Y/Y)
Operating loss
-$7,197K
(-9.13%↓ Y/Y)
Research and development
$4,684K
(29.64%↑ Y/Y)
General and
administrative
$2,513K
(-15.73%↓ Y/Y)
Buy us a coffee
Nuvectis Pharma, Inc. (NVCT)
Nuvectis Pharma, Inc. (NVCT)